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Ion channels are key regulators of cancer cell pathophysiology. They contribute to a variety 
of processes such as maintenance of cellular osmolarity and membrane potential, motility 
(via interactions with the cytoskeleton), invasion, signal transduction, transcriptional activity 
and cell cycle progression, leading to tumour progression and metastasis. Ion channels thus 
represent promising targets for cancer therapy. Ion channels are attractive targets because 
many of them are expressed at the plasma membrane and a broad range of existing 
inhibitors are already in clinical use for other indications. However, many of the ion channels 
identified in cancer cells are also active in healthy normal cells, so there is a risk that certain 
blockers may have off-target effects on normal physiological function. This review describes 
recent research advances into ion channel inhibitors as anticancer therapeutics. A growing 
body of evidence suggests that a range of existing and novel Na+, K+, Ca2+ and Cl- channel 
inhibitors may be effective for suppressing cancer cell proliferation, migration and invasion, 
as well as enhancing apoptosis, leading to suppression of tumour growth and metastasis, 
either alone or in combination with standard of care therapies. The majority of evidence to 
date is based on preclinical in vitro and in vivo studies, although there are several examples 
of ion channel targeting strategies now reaching early phase clinical trials. Given the strong 
links between ion channel function and regulation of tumour growth, metastasis and 
chemotherapy resistance, it is likely that further work in this area will facilitate the 





Traditional chemotherapeutic approaches have been successfully used as cancer treatments 
for decades, partially due to their generalised, anti-proliferative and cytotoxic activity (DeVita 
and Chu, 2008). However, the lack of specificity of chemotherapy is a limiting factor in the 
treatment of more advanced tumours and acquired resistance. This has driven the 
development of targeted therapies, such as monoclonal antibodies, small molecule pathway 
inhibitors, immune check-point inhibitors and emerging cellular therapies (Baudino, 2015). 
The limitations of targeted treatments can come from their specificity, making their 
effectiveness tumour- or antigen-dependent, and thus potentially only applicable to a 
relatively small proportion of the population. A relatively underexplored area in cancer 
research is represented by the therapeutic targeting of ion channels and transporters 
(Oosterwijk and Gillies, 2014). Plasma membrane ion channels have been shown to 
contribute to a variety of cellular processes in addition to their role in maintaining membrane 
potential (Vm) and cellular osmolarity (Yang and Brackenbury, 2013, Djamgoz et al., 2014, 
Leslie et al., 2019). For example, as discussed in detail elsewhere in this series of Special 
Issues, alterations in ion flux can contribute to cellular motility, cytoskeletal rearrangements 
and signal transduction underpinning cellular migration (Schwab et al., 2012, Yang et al., 
2020), growth and cell cycle progression (Blackiston et al., 2009, Urrego et al., 2014, 
Humeau et al., 2018), gene expression (Mycielska et al., 2005, Popov et al., 2012), as well 
as defining the extracellular environment (e.g. pH regulation (Parks et al., 2013, Wu et al., 
2017)). In the tumour microenvironment, higher levels of K+ and Na+ have been reported, 
accompanied by a relatively decreased pH and hypoxic environment compared to healthy 
tissue (Ouwerkerk et al., 2007, Eil et al., 2016, Leslie et al., 2019). Elevated expression of a 
wide range of ion channels has also been associated with metastasis, reviewed extensively 
elsewhere (Pardo and Stuhmer, 2014, Brackenbury, 2016, Djamgoz et al., 2019). Together, 
these findings suggest that ion channels could serve as potential targets for anticancer 
therapies, particularly given the tumour-specific expression of certain channel types. Ion 
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channels, particularly those at the plasma membrane, present potentially attractive 
therapeutic targets due to their location and the fact that a broad range of existing inhibitors 
are already in clinical use. Given that many blockers of plasma membrane ion channels can 
act extracellularly, they can be screened relatively easily using electrophysiological 
approaches. Intracellular ion channels have also been shown to be important regulators of 
cancer cell metabolism, apoptosis and gene expression (Leanza et al., 2013a, Jang et al., 
2015, Peruzzo and Szabo, 2019); these could similarly represent attractive targets for 
therapeutic inhibition. 
 
On the other hand, given that many of the ion channels identified in cancer cells are 
expressed in healthy normal cells, there is a risk that these blockers may have off-target 
effects on normal physiological function. This review describes recent research advances 
into ion channel inhibitors for cancer treatment. Key Na+, K+, Ca2+ and Cl- channel inhibitors 
are covered, followed by details on their use and effectiveness in cancer, as well as 
considering combining such inhibitors with standard of care therapies (Figure 1). 
 
Na+ Channel Inhibitors 
 
Several classes of Na+ channels have been shown to be aberrantly expressed in cancer cells 
where they regulate cell proliferation, migration, invasion and metastasis (Leslie et al., 2019). 
In particular, voltage gated Na+ channels (VGSCs) are upregulated in tumour cells where 
their activity regulates Vm, morphological changes and metastatic behaviour (Grimes et al., 
1995, Roger et al., 2003, Fraser et al., 2005, Nelson et al., 2014, Nelson et al., 2015, Yang et 
al., 2020). VGSCs have thus been studied as potential cancer targets (Table 1). VGSCs are 
important clinical targets for the treatment of epilepsy and cardiac arrhythmia (George, 2005, 
Mantegazza et al., 2010). Various Class 1B antiarrhythmic drugs, antiepileptic drugs and 
local anaesthetics have been studied in preclinical in vitro and in vivo cancer models (Martin 
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et al., 2015). For example, the anticonvulsant phenytoin inhibits breast cancer cell migration, 
tumour growth, invasion and metastasis (Yang et al., 2012, Nelson et al., 2015). Phenytoin 
also inhibits migration and secretory activity in prostate and lung cancer cells (Abdul and 
Hoosein, 2001, Fraser et al., 2003b, Onganer and Djamgoz, 2005). These results are 
generally supported by other studies using different VGSC-inhibiting drugs in breast cancer 
and other cancer types, including carbamazepine, riluzole, ranolazine and ropivacaine (Abdul 
and Hoosein, 2001, Abdul and Hoosein, 2002b, Yip et al., 2009, Speyer et al., 2012, 
Djamgoz and Onkal, 2013, Baptista-Hon et al., 2014, Driffort et al., 2014, Bugan et al., 2019, 
Guzel et al., 2019). It should be noted, however, that some compounds may elicit their 
anticancer effects through other mechanisms in addition to VGSC inhibition. For example, 
riluzole may prevent migration or promote apoptosis and cell cycle arrest (shown in glioma, 
neuroblastoma, lung, colon and prostate cancer) and inhibit autophagy (shown in pancreatic 
cancer) at least in part via its function as a non-competitive inhibitor of the metabolic 
glutamate receptor 1 (Akamatsu et al., 2009, Zhang et al., 2015, Seol et al., 2016, Lemieszek 
et al., 2018, Sun et al., 2019). Nonetheless, a number of studies now show that VGSC-
inhibiting drugs suppress proliferation, promote apoptosis, and reduce migration, invasion 
and metastasis (Martin et al., 2015). 
 
A key advantage of Class 1B antiarrhythmic drugs is that they display state-dependent 
binding and preferentially block VGSCs in the inactivated state (Clare et al., 2000). 
Accumulating evidence suggests that cancer cells have a relatively depolarised Vm, which 
would mean that VGSCs present in these cells are predominantly in their inactivated state 
(Yang and Brackenbury, 2013). Importantly, studies have shown that VGSCs expressed in 
cancer cells, including Nav1.5, carry a small persistent Na+ current in the inactivated state 
which depolarises the Vm further and permits cytosolic Na+ accumulation (Gillet et al., 2009, 
Brisson et al., 2011, Yang et al., 2012, Campbell et al., 2013, Yang et al., 2020). Further 
evidence suggests that this persistent Na+ current is critical for promoting metastatic cell 
behaviour (Driffort et al., 2014, Nelson et al., 2015). Therefore, state-dependent VGSC 
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blockers which preferentially bind to VGSCs in the inactivated state are likely to selectively 
target tumour-expressing VGSCs whilst leaving VGSCs in other cells, e.g. cardiomyocytes 
and neurons, unaffected. There is, however, currently a lack of clinical data in support of this 
hypothesis. Although the VGSC-inhibiting drugs valproate and quinidine have been studied 
in clinical trials, their mode of action via Na+ current suppression was not investigated 
(Raderer et al., 1993, Wheler et al., 2014). The therapeutic value of VGSC inhibitors in the 
context of cancer has been studied retrospectively in several observational cohort data 
studies (Walker et al., 2011, Fairhurst et al., 2014, Fairhurst et al., 2015, Reddy et al., 2015, 
Fairhurst et al., 2016, Takada et al., 2016). However, the results are inconsistent, with 
several studies demonstrating positive associations (Exadaktylos et al., 2006, Biki et al., 
2008, Walker et al., 2011, Reddy et al., 2015, Takada et al., 2016) and another study 
showing a negative association, although the possibility of confounding by indication cannot 
be excluded (Fairhurst et al., 2015). Thus, prospective clinical trials are required to establish 
the utility of VGSC inhibition in cancer patients (Djamgoz et al., 2019). 
 
Novel compounds have also been investigated as potential inhibitors of VGSC function in 
cancer cells. Novel α-hydroxy-α-phenylamide analogues of phenytoin have been developed 
in order to improve VGSC subtype specificity and some of these have been shown to inhibit 
prostate cancer cell proliferation (Anderson et al., 2003, Lenkowski et al., 2004). Additional 
small molecule VGSC inhibitors have been developed with the aim of increasing selectivity 
for the neonatal splice variant of Nav1.5 expressed in breast cancer cells and these have 
been shown to inhibit both Na+ current and invasion (Dutta et al., 2018). The casein kinase 1 
inhibitor IC261, which induces cell cycle arrest and apoptosis in cancer cell lines, has also 
been shown to inhibit Nav1.5 currents, suggesting that IC261 may elicit its anti-tumour effects 
partially though VGSC inhibition (Brockschmidt et al., 2008, Föhr et al., 2017). The mexiletine 
analogue RS10064, targeted at tetrodotoxin-resistant VGSCs, inhibits oxidative stress 
induced by tumour development in the DMBA rat breast cancer model (Batcioglu et al., 
2012). ω-3 polyunsaturated docosahexaenoic acid, which has been shown to improve breast 
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cancer outcomes, inhibits Nav1.5 expression and activity in breast cancer cells via 
peroxisome proliferator-activated receptor β (PPARβ) (Isbilen et al., 2006, Gillet et al., 2011, 
Wannous et al., 2015). 
 
Numerous peptide toxins bind to and inhibit VGSCs, and several of these have been 
explored in the context of cancer treatment. Local injection of the pan-specific VGSC-
inhibiting toxin tetrodotoxin directly into subcutaneous prostate tumours in rats significantly 
reduces lung metastasis, improving survival (Yildirim et al., 2012). Treatment of prostate 
cancer cells with the tarantula peptide toxin HNTX-III derived from the venom of 
Selenocosmia hainana downregulates Nav1.7, decreases RhoA/Rac1 protein expression and 
inhibits cellular migration, raising the possibility that such isoform-specific toxins may have 
utility as anti-motility drugs (Chen et al., 2019). However, a potential issue with peptide toxins 
such as tetrodotoxin is that, unlike Class 1B antiarrhythmic drugs, they do not display state-
dependent binding. Thus, it would not be possible to administer such agents systemically 
without toxic side-effects. Nonetheless, chemical modification of these toxins to aid tumour-
specific targeting may be possible. One further issue with the use of VGSC inhibitors in 
general, including state-dependent blockers, is that they may also inhibit VGSCs present on 
immune cells, potentially reducing a desirable anti-tumour immune response. For example, 
Nav1.5 is expressed on CD4+ T cells where it plays a role in positive selection (Lo et al., 
2012). 
 
There has also been interest in developing ion-channel targeting monoclonal antibodies. This 
has proven to be relatively challenging given the complex structure of ion channel proteins, 
which makes it difficult to identify suitable epitopes, as well as due to the complexity of 
manufacturing antibodies, compared to small molecule design (Hutchings et al., 2019). A 
polyclonal antibody directed at the neonatal Nav1.5-specific D1:S3/4 linker inhibits Na+ 
current with high specificity for neonatal Nav1.5 versus the adult splice variant (Chioni et al., 
2005). Importantly, this antibody was additionally shown to inhibit migration and invasion of 
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breast cancer cells (Brackenbury et al., 2007). Although the primary purpose of such 
antibodies has been to inhibit channel function, an additional possibility is that these 
antibodies may have utility as diagnostic tools (Yamaci et al., 2017) and/or as vehicles to 
target cytotoxic therapies to tumours (Arcangeli et al., 2009). 
 
Epithelial Na+ channels (ENaC) from the ENaC/degenerin family are also important players in 
metastatic cell behaviour (Yamamura et al., 2008, Bondarava et al., 2009, Del Monaco et al., 
2009, Kapoor et al., 2009, Xu et al., 2016). ENaC activity promotes proliferation and inhibits 
apoptosis of hepatic carcinoma cells, as part of a hypertonicity-induced cationic channel 
complex (Sparks et al., 1983, Vila-Carriles et al., 2006, Bondarava et al., 2009). More 
recently, ENaC expression has been associated with increased expression of the achaete-
scute homolog 1 (ASCL-1) transcription factor that mediates growth and progression of lung 
tumours (He et al., 2018). The exact mechanism that connects ENaC and ASCL-1 has not 
been fully defined, but these findings suggest that ENaC might contribute to tumour growth 
as a transcriptional target of ASCL-1 (He et al., 2018). Acid-sensing ion channels (ASIC), 
also members of the ENaC/degenerin family, can enhance invasive behaviour by activating 
the calcineurin/Nuclear Factor of Activated T Cells 1 (NFAT1) pathway in colorectal cancer 
cells and treatment with cyclosporin A was shown to block the calcineurin pathway and 
ASIC2- mediated metastasis (Zhou et al., 2017). ASIC1 and 3 promote epithelial to 
mesenchymal transition in pancreatic cancer cells in a Ca2+-dependent manner (Zhu et al., 
2017). The ENaC-inhibiting K+-sparing diuretic amiloride has been shown to suppress ENaC-
induced chorionic carcinoma cell migration in response to aldosterone (Del Monaco et al., 
2009). Together with further studies showing anti-tumour and anti-metastatic effects of 
amiloride, these data suggest that pharmacological blockade of ENaC/ASIC channels may 
have therapeutic relevance (Matthews et al., 2011). 
 
The ATP-dependent Na+/K+ pump (also known as the Na+/K+ ATPase) is an important 
regulator of Na+/K+ homeostasis in cancer cells (Zhang et al., 2008, Schneditz et al., 
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2019).This pump is the key membrane protein for transporting Na+ out from the cell and 
maintaining a stable Vm (Post et al., 1969). Na+/K+ ATPase expression is elevated in breast 
cancer cells compared to normal epithelial cells and its activity promotes proliferation, 
migration and invasion (Li et al., 2017, Khajah et al., 2018). Different Na+/K+ ATPase α 
subunit isoforms have been associated with cancer malignancy: α1 mostly correlates with 
early stages of cancer (including prostate, lung and renal tumours), whilst α3 associates with 
advanced disease (Felippe Goncalves-de-Albuquerque et al., 2017). Cardiac glycoside 
digitalis drugs, e.g. ouabain, digoxin, which are potent inhibitors of the Na+/K+ ATPase (Post 
et al., 1969, Laursen et al., 2013), have been shown to inhibit proliferation, migration, 
invasion, inflammation, tumour growth and promote lysis of cancer cells (Zhang et al., 2008, 
Kepp et al., 2012, Gould et al., 2018, Khajah et al., 2018), reduce risk of certain cancers 
(Haux et al., 2001) and improve survival (Menger et al., 2012). Inhibition of the Na+/K+ 
ATPase by digitalis drugs leads to intracellular accumulation of Na+ and subsequent reverse 
mode operation of the Na+/Ca2+ exchanger (NCX) causing an increase in intracellular Ca2+, 
which may then impact on cell cycle progression and survival (Chen et al., 2014). 
Interestingly, studies have shown that while the ion transport function of the Na+/K+ ATPase 
is inhibited by cardiac glycosides, these can enhance signalling via the pump, inducing 
activation of an associated kinase – Src, which transactivates the epidermal growth factor 
receptor (EGFR), forming a signalling complex that induces activation of mitogen-activated 
kinase (MAPK), thus indicating a complex function of the Na+/K+ pump in maintaining cellular 
physiology (Haas et al., 2002). Although the Na+/K+ ATPase was long thought to be the only 
target of ouabain and other digitalis drugs, there is emerging evidence suggesting that these 
compounds modulate additional targets, such as the X-hepatic receptor (Campia et al., 2012) 
and the steroid receptor co-activators (SRC) 1 and 3 (Wang et al., 2014). Thus, effects on 




In summary, a growing body of evidence suggests that pharmacological inhibition of various 
classes of Na+ channels and transporters in cancer cells can inhibit proliferative and invasive 
capacity and may promote cell death. Further work is required to fully delineate the 
mechanism(s) of action of a number of these compounds in cancer cells and their potential 
clinical value. 
 
K+ Channel Inhibitors 
 
Many plasma membrane K+ channels are aberrantly expressed in cancer cells where their 
expression is often associated with increased proliferative capacity, and a number of these 
have been explored as therapeutic targets (Table 2) (Huang and Jan, 2014, Pardo and 
Stuhmer, 2014). For example, the Kv1.3 voltage-gated K+ channel (VGKC) plays a role in 
regulation of proliferation in brain cell progenitors, but also in cancer cells (Fraser et al., 
2000, Chittajallu et al., 2002, Fraser et al., 2003a). In prostate cancer cells, Kv1.3 was shown 
to be sensitive to several drugs, including dequalinium, glyburide and amiodarone, which 
induced growth inhibition and cell death (Abdul and Hoosein, 2002a). In addition, Kv1.3 
currents in prostate cancer cells are sensitive to verapamil, margatoxin, charybdotoxin, 4-
aminopyridine and tetraethylammonium (Fraser et al., 2003a). In melanoma cells, treatment 
with the Kv1.3 inhibitors tetraethylammonium, verapamil and fampridine was shown to disrupt 
the interaction between Kv1.3 channels and β1 integrin, suggesting that integration of VGKCs 
in macromolecular protein complexes might provide a role in tumour cell adhesion and 
invasion (Artym and Petty, 2002).  
 
Another VGKC widely studied in the context of cancer is Eag1 (Kv10.1) (Ouadid-Ahidouch et 
al., 2016). Kv10.1 is upregulated in a number of tumour types (Ding et al., 2007, Ousingsawat 
et al., 2007). Kv10.1 promotes proliferation in cancer cell lines and over-expression in 
Chinese hamster ovary cells causes tumorigenesis in vivo (Pardo et al., 1999, Ouadid-
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Ahidouch et al., 2001). Direct targeting of Kv10.1 with monoclonal antibodies inhibits K+ 
currents and has an anti-proliferative effect, reducing tumour growth in vivo (Gómez-Varela 
et al., 2007). Furthermore, development of a bifunctional antibody carrying a human Kv10.1 
recognition site and a human TNF-related apoptosis-inducing ligand (TRAIL) domain was 
shown to induce selective apoptosis in prostate cancer cells sensitised with cytotoxic drugs 
(Hartung et al., 2011). Other well-established inhibitors of human Eag1 include astemizole 
and imipramine (Garcia-Ferreiro et al., 2004). Imipramine was shown to inhibit proliferation 
and induce apoptotic behaviour in ovarian cancer cells (Asher et al., 2011). Astemizole has 
also been shown to inhibit proliferation in vitro and tumour growth in vivo (Garcia-Quiroz and 
Camacho, 2011, de Guadalupe Chavez-Lopez et al., 2015, Bernal-Ramos et al., 2017). In 
addition, the sea anemone toxin APETx4 inhibits Kv10.1, although it is cytotoxic in both 
cancer and non-cancer cell lines (Moreels et al., 2017b). Several novel purpurealidin 
analogues were also found to inhibit Kv10.1 current and increase cell death (Moreels et al., 
2017a). 
 
HERG (Kv11.1) is primarily associated with cardiac arrhythmias, but is also upregulated in 
various cancers (Cherubini et al., 2000, Pillozzi et al., 2002, Lastraioli et al., 2004, Lastraioli 
et al., 2006). As with Kv10.1, Kv11.1-mediated K+ current has been shown to increase cancer 
cell proliferation (Bianchi et al., 1998, Wang et al., 2002, Arcangeli, 2005). In addition, Kv11.1 
interacts with b1 integrin, promoting adhesion interactions and adhesion-dependent 
signalling to regulate cancer cell survival, migration, invasion and chemoresistance 
(Cherubini et al., 2005, Arcangeli and Becchetti, 2006, Pillozzi et al., 2007, Pillozzi et al., 
2011, Crociani et al., 2013). Kv11.1 has been studied as a potential cancer target and anti-
cancer agents, e.g. tamoxifen, have been shown to have an inhibitory effect on channel 
function (Thomas et al., 2003). The Kv11.1 inhibitor cisapride has also been shown to inhibit 
proliferation of gastric cancer cells (Shao et al., 2005). In addition, the Kv11.1 inhibitor E4031 
reduced infiltration of acute lymphoblastic leukaemia cells in a mouse model, increasing 
survival (Pillozzi et al., 2011). E4031 and another Kv11.1 inhibitor (WAY123,398) also 
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suppress gastric and colorectal cancer growth, angiogenesis (by PI3K/ β1-intergin-mediated 
Akt activation leading to vascular endothelial growth factor (VEGF)-A transcription) and 
metastasis in mice (Crociani et al., 2013, Crociani et al., 2014). E4031 was also shown to 
inhibit colon cancer cell proliferation and Kv11.1 was identified as a biomarker of colon 
cancer in patient samples (Dolderer et al., 2010). E4031 and a second Kv11.1 inhibitor, 
ergtoxin, were shown to inhibit proliferation of ovarian cancer cells by inhibiting cell cycle 
progression, but without inducing apoptotic behaviour (Asher et al., 2011). A potential issue 
with the use of Kv11.1 blockers is the risk of off-target effects, specifically slowed cardiac 
repolarization and ventricular arrhythmia (Arcangeli et al., 2009). However, this may be 
overcome by the use of state-dependent blockers targeting Kv11.1 in the open state in 
cancer cells, whilst leaving cardiac Kv11.1 channels in the inactivated state unaffected 
(Arcangeli et al., 2009). Kv11.1-targeting monoclonal antibody-nanoparticle conjugates have 
also been explored as potential vehicles to deliver photodynamic therapies for pancreatic 
cancer (Sette et al., 2013) and novel recombinant anti-Kv11.1 single chain fragment variable 
antibodies have been developed and evaluated for cancer molecular imaging (Duranti et al., 
2018, Duranti and Arcangeli, 2019). 
 
The K+ 2 pore domain (K2P) channels, which contribute to setting the resting Vm, are also 
upregulated in a variety of cancers including breast, colon, prostate and lung tumours and 
have been shown to promote proliferation (Mu et al., 2003, Kim et al., 2004, Voloshyna et al., 
2008). However, some members of this family appear to be downregulated in other tumour 
types, suggesting a complex function of K2P channels in cancer progression (Williams et al., 
2013). A monoclonal antibody against the extracellular domain of K2P9.1 has been shown to 
inhibit tumour growth and metastasis in mice (Sun et al., 2016). Ca2+-activated K+ channels 
are also expressed in cancer cells (Brackenbury, 2016). The large conductance KCa1.1 
channel promotes proliferation of HeLa cervical cancer cells, and this can be inhibited by 
treatment with the KCa1.1 blocker iberiotoxin (Han et al., 2007). In addition, iberiotoxin causes 
cell cycle arrest and apoptosis in glioma cells (Weaver et al., 2004). The vitamin D receptor 
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agonists calcitriol and calcipotriol, and the androgen receptor antagonists bicalutamide and 
enzalutamide inhibit KCa1.1 expression in breast cancer cells, suggesting that these 
compounds may also elicit antiproliferative activity via KCa1.1 inhibition (Khatun et al., 2016, 
Khatun et al., 2018). The intermediate conductance KCa3.1 channel blocker TRAM-34 inhibits 
cell cycle progression of B lymphoma cells induced by serum (Wang et al., 2007). The same 
study also showed that the CD20-targeting monoclonal antibody rituximab also inhibits 
KCa3.1 activity (Wang et al., 2007). Similarly, TRAM-34 inhibits proliferation and migration 
and promote apoptosis of breast cancer cells (Zhang et al., 2016). TRAM-34 also inhibits 
KCa3.1-mediated glioma cell migration and invasion (Turner et al., 2014). In addition, KCa3.1 
overexpression in breast cancer cells promotes tumour growth and metastasis (Thurber et 
al., 2017). However, in pancreatic cancer cells, although TRAM-34 inhibited KCa3.1 currents, 
it actually promoted migration and invasion, suggesting potential anomalous effects of this 
compound and/or target (Bonito et al., 2016). Inhibition of small conductance KCa2.3 
channels with tetraethylammonium, apamin and 4-aminopyrimidine decreased breast cancer 
cell migration in vitro (Potier et al., 2006) and recently new lipophilic pyridine and 
tetrahydropyridine derivatives have been designed and synthesised which inhibit KCa2.3 
channel activity and cellular migration (Kouba et al., 2020).  
 
Targeting intracellular K+ channels may also derive benefit. Mitochondrial Kv1.3 is widely 
expressed in various tissues, and a nuclear Kv1.3 was also identified in some breast, lung 
and gastric adenocarcinoma cell lines, as well as in lymphocytes and brain cells. Nuclear 
Kv1.3 functions as a regulator of gene expression by interacting with the cAMP response 
element-binding protein (CREB) and the c-FOS transcription factors (Jang et al., 2015). 
Mitochondrial Kv1.3 interacts with the Bcl-2 family protein, Bax, which inhibits the activity of 
the channel, inducing cytochrome c cytoplasmic release and subsequent apoptosis (Szabó 
et al., 2008, Szabò et al., 2011). Pharmacological inhibition of intracellular Kv1.3 with Psora-
4, clofazimine and 5-(4-Phenoxybutoxy)psoralen (PAP1) induces apoptosis in lymphocyte, 
fibroblast, bone, skin cancer cell lines in a Bax/Bak-independent manner. Furthermore, the 
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same inhibitors induce apoptosis in patient-derived leukaemia B cells and clofazimine 
reduces melanoma tumour growth in vivo (Leanza et al., 2012, Leanza et al., 2013b).  
 
Kv10.1 is also expressed in the nuclear membrane of malignant brain colon and ovarian 
cancer cells, as well as leukaemia and fibrosarcoma (Martínez et al., 2015, Peruzzo et al., 
2016). Given its location, it has been suggested that Kv10.1 might also impact on gene 
expression. However, unlike Kv1.3 its pro-tumorigenic function seems to occur through 
changes in channel conformation rather than through K+ transport (Hegle et al., 2006, Chen 
et al., 2011). KCa3.1 and VGKCs have also been identified in mitochondria of melanoma, 
colon and breast cancer cells where they regulate oxidative phosphorylation and proliferation 
(Kovalenko et al., 2016). Combined activation of membrane and mitochondrial KCa3.1 is 
associated with breast tumour resistance to radiotherapy in vivo (Mohr et al., 2019). In 
addition, intracellular KCa3.1 is sensitive to inhibition by TRAM-34 and clotrimazole (De 
Marchi et al., 2009). Elevated intracellular KCa1.1 has been reported in the endoplasmic 
reticulum (ER), nucleus and Golgi of pancreatic cancer cells (Singh et al., 2012). Bax-
mediated inhibition of mitochondrial KCa1.1 promotes apoptosis by enhancing the formation 
of the mitochondrial permeability transition pore (Cheng et al., 2011). The mitochondrial acid 
sensing K+ channel, TASK3, mediates survival and maintains mitochondrial integrity in 
melanoma cells (Kosztka et al., 2011, Nagy et al., 2014). Furthermore, inhibition of TASK3 
with Zn2+ or methanandamide slows proliferation of ovarian cancer cells, suggesting that it 
might serve as a valuable target (Innamaa et al., 2013). 
 
In summary, various classes of plasma membrane and intracellular K+ channels are 
upregulated in cancer cells and a number of studies point to pharmacological inhibition of 
specific subtypes as an effective approach to suppress proliferation, migration and invasion, 
and increase apoptosis. 
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Ca2+ Channel Inhibitors 
 
A number of different types of plasma membrane Ca2+ channel have been documented in 
cancer cells that could be targeted therapeutically (Table 3) (Lee et al., 2011, Prevarskaya et 
al., 2011, Bong and Monteith, 2018, Gautier et al., 2019). Upregulation of L-type (Cav1.x) and 
T-type (Cav3.x) voltage-gated Ca2+ channels promotes differentiation, secretion of mitogenic 
factors, proliferation and angiogenesis (Bertolesi et al., 2002, Mariot et al., 2002, Sun et al., 
2006, Gackiere et al., 2008, Lu et al., 2008). Emerging preclinical evidence suggests that 
repurposing Cav channel-inhibiting drugs to cancer may be beneficial (Buchanan and 
McCloskey, 2016). For example, mibefradil and the Cav3.x inhibitor NNC-55-0396 have been 
shown to reduce cell proliferation and induce cell apoptosis in leukaemia cell lines (Huang et 
al., 2015). Inhibition of Cav1.3 in endometrial carcinoma cells with nifedipine reduced 
proliferation and migration and induced autophagy (Bao et al., 2012). Nifedipine has also 
been shown to inhibit proliferation of breast cancer cells (Squecco et al., 2015). In addition, 
the Cav3.x blocker KYS05090 has been shown to induce apoptosis and autophagy in lung 
cancer cells, although the mechanism may be channel independent (Rim et al., 2014).  
 
The store operated Ca2+ channel proteins also play an oncogenic role (Yang et al., 2009). 
ORAI1 and ORAI3 heterodimerise to support Ca2+ influx and promote proliferation (Dubois et 
al., 2014). Furthermore, the store operated Ca2+ channel blocker SKF96365 inhibits breast 
cancer metastasis in mice (Yang et al., 2009). Various transient receptor potential (TRP) 
channels, activated by extracellular stimuli e.g. pH, mechanical stimuli, are also expressed in 
cancer cells and can promote proliferation, survival angiogenesis and metastasis (Thebault 
et al., 2006, Bidaux et al., 2007, Lehen'kyi et al., 2007, Bolanz et al., 2008, Bomben and 
Sontheimer, 2008, Guilbert et al., 2009, Fiorio Pla et al., 2012). However, there are some 
exceptions, e.g. TRPM6, which is downregulated in colorectal tumours and associates with 
improved survival (Xie et al., 2018) and TRPM8, which inhibits migration (Genova et al., 
2017). Treatment of breast cancer cells with the TRP channel inhibitor 2-
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aminoethoxydiphenyl borate (2-APB) has been shown to decrease proliferation by damaging 
DNA (Hopkins et al., 2015). The specific TRPM7 inhibitor waixenicin A significantly 
decreased colon cancer cell proliferation in vitro but had no impact on aberrant crypt foci 
development in vivo, highlighting the importance of model selection in screening of channel 
inhibitors (Huang et al., 2017). In addition, given the complex involvement of various TRP 
channel subtypes in promoting/inhibiting cancer progression, channel inhibition will not be 
appropriate in certain circumstances. For example, the TRPM8 agonist WS12 suppresses 
endothelial cell migration and prostate cancer metastasis in mouse models (Genova et al., 
2017, Grolez et al., 2019). Nonetheless, TRP channel inhibitors have been studied in the 
clinical setting. The TRPV6 inhibitor SOR-C13 recently went into first-in-human phase I study 
in patients with advanced solid tumours and disease stabilisation in the treated cohort 
suggested potential anti-tumour activity (Fu et al., 2017).  
 
The purinergic P2X7 cation channel has also gained interest in the context of cancer, 
although conflicting results from different studies have been challenging to interpret (Roger et 
al., 2015). However, a monoclonal antibody targeting a unique epitope on the cancer-specific 
variant of P2X7 (nfP2X7) has undergone Phase 1 clinical trial for basal cell carcinoma with 
promising results including disease stabilisation, partial and complete response (Gilbert et 
al., 2017, Gilbert et al., 2019).  
 
In colon cancer cells, the cannabinoid cannabigerol suppresses proliferation and promotes 
reactive oxygen species (ROS) production and apoptosis via TRPM8 inhibition, and slows 
tumour growth in vivo (Borrelli et al., 2014). In addition, upregulation of TRPV1 has been 
identified as a key player in cannabinoid-derivative-induced apoptosis of cervical cancer and 
glioma cells (Contassot et al., 2004a, Contassot et al., 2004b). Other studies, however, 
propose different mechanisms for the anti-cancer activity of cannabinoids (Hamtiaux et al., 
2011), for example, by interacting with the cannabinoid receptor 2 in addition to TRPV1 
activation (Ligresti et al., 2006). 
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Intracellular Ca2+ channels may also present potential targets. For example, TRPM8 and 
TRPC1 both play a role in survival and proliferation of tumour cells (Zhang and Barritt, 2004, 
Shapovalov et al., 2016). TRPM8 inhibition with capsazepine reduces survival of prostate 
cancer cells, and TRPM8 knockdown slows proliferation of osteosarcoma cells by interfering 
with Ca2+-dependent Akt function (Zhang and Barritt, 2004, Wang et al., 2013). TRPC1 
regulates glioma cell division and its inhibition with 2-APB, MRS-1845 and SKF96365 inhibits 
proliferation in vitro and reduces tumour size in mouse models (Bomben and Sontheimer, 
2010). Ryanodine receptors promote breast cancer cell survival and their expression 
correlates with tumour grade; in addition, the ryanodine receptor inhibitor 4-chloro-m-cresol 
inhibits breast cancer cell proliferation in vitro (Abdul et al., 2008). Furthermore, treatment of 
lung cancer cells with the ryanodine receptor inhibitor 20-O-β-D-glucopyranosyl-20(S)-
protopanaxadiol induces Ca2+-dependent apoptosis, supporting the essential role of these 
channels in cancer cell survival (Shin et al., 2018). 
 
In summary, a number of Ca2+ channel inhibitors have shown promise in preclinical studies 
and some of these have now reached clinical trials. Several epidemiological studies show 
that existing Ca2+ channel blockers are not associated with increased cancer risk (Grimaldi-
Bensouda et al., 2016, Wilson et al., 2016, Brasky et al., 2017), supporting a compelling 
argument for further exploration of the possibility of repurposing such drugs to treat cancer 
(Buchanan and McCloskey, 2016). However, the complex opposing roles of some Ca2+ 
channels in cancer cells, e.g. certain TRP and P2X7 channels, highlights the importance of 
fully understanding their diverse physiological roles in order to permit appropriate targeting. 
 
Cl- Channel Inhibitors 
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Several Cl- channels have been shown to be aberrantly expressed in cancer cells, 
contributing to survival and progression and some have been explored as therapeutic targets 
(Table 4). The ionotropic Cl--permeant GABAA receptor is upregulated on metastatic breast 
cancer cells in the brain (Neman et al., 2014), which themselves promote altered regional 
excitability (Simon et al., 2020). The voltage-gated Cl- channels CLC-2 and CLC-3 are 
functionally active in glioma cells and the latter is essential for facilitating mitosis and 
invasion by regulating cell volume (Olsen et al., 2003, Habela et al., 2008, Lui et al., 2010, 
Watkins and Sontheimer, 2011). CLC-3 also stimulates breast cancer cell proliferation and 
tumour growth (Zhou et al., 2018) and promotes migration of nasopharyngeal carcinoma 
cells (Mao et al., 2008). However, other studies have indicated that CLC-3 can also promote 
apoptosis (Liu et al., 2013), thus cancer-promoting or inhibiting activity of this channel is 
likely finely tuned and may be context dependent (Hong et al., 2015). CLC-3 is sensitive to 
non-specific Cl- channel inhibitors such as tamoxifen and 4-5-nitro-2-(3-phenylpropylamino) 
benzoic acids (NPPBs) (Wang et al., 2012), inhibiting cancer cell proliferation (Shen et al., 
2000). Similarly, tamoxifen was shown to only have an inhibitory effect on cancer cell 
migration in the presence of CLC-3, likely as a result of dysregulated cell volume 
management and therefore cell cycle stagnation (Mao et al., 2013).  
 
Hydrolysis products of 4,4-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS), which are 
inhibitors of anion permeability, can inhibit CLC family channels, as can phenylalanine 
derivatives (stilbenes), clofibric acids, benzofurans, and the newer benzimidazole derivative, 
BIM1 (Matulef et al., 2008, Koster et al., 2018). However, the broad effect of such 
compounds on other Cl- channels remains a challenge with respect to potential off-target 
effects (Hong et al., 2015) and applicability in cancer treatment needs to be confirmed 
through further studies. Specific function-blocking antibodies targeting CLC-3 have been 
developed (Wang et al., 2003) but their efficacy in cancer models remains to be determined. 
Chlorotoxin, a scorpion toxin identified as a CLC-3 inhibitor, binds to a membrane-bound 
matrix metalloproteinase on glioma cells (Deshane et al., 2003). Radiolabelled I131-
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chlorotoxin has undergone a Phase 1 clinical trial in adult patients with high grade glioma 
with the aim of improving targeted radiation to the tumour site and demonstrated good 
tolerability and potential anti-tumoral effects (Mamelak et al., 2006). 
 
The anoctamin Ca2+ -dependent Cl- channels promote cancer cell proliferation and apoptosis 
of cancer cells under certain conditions (Kunzelmann et al., 2019). Inhibition of 
ANO1/TMEM16 with the specific inhibitor CaCCinh-A01 significantly decreased tumour 
progression, raising the possibility that this channel may be a potential therapeutic target 
(Britschgi et al., 2013). An important regulator of the Cl- concentration within developing glial 
cells is the Na+/ K+/ 2Cl- cotransporter (NKCC1). NKCC1 has been proposed as a key 
promoter of glioma cell migration, being localized at the tip of the migratory pole of the cell 
and also influences cell-cell adhesion and Cl- -dependent cell volume regulation (Habela et 
al., 2009, Garzon-Muvdi et al., 2012). Treatment with the NKCC1 inhibitor bumetanide 
inhibits migration of metastatic glioma cells both in vivo and in vitro, suggesting that NKCC1 
could be a promising target in the treatment of glioma (Haas and Sontheimer, 2010). 
 
In lung cancer cells, the Cl- intracellular channel 1 (CLIC1), which can be found both at the 
plasma membrane and in the cytosol, suppresses Ca2+ import via L-type Ca2+ channels, 
promoting survival (Lee et al., 2019b). In silico analysis showed a much higher risk of death 
in breast, pancreatic and liver cancer patients with high CLIC1 expression, while gastric 
cancer patients with high CLIC1 levels have a survival advantage, suggesting that its 
function might vary with depending on tumour type (Gururaja Rao et al., 2020). Further work 
is required to establish the therapeutic value of CLIC1 inhibition, and/or inhibition of other 
intracellular Cl- channel subtypes, e.g. CLIC4 (Fernández-Salas et al., 2002, Zhong et al., 
2012).  
 
In summary, both plasma membrane and intracellular Cl- channels are important regulators 
of cell cycle, proliferation and migration, making them promising targets for cancer therapies. 
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Although some inhibitory molecules have been found effective in reducing tumour cell growth 
and migration, there is a strong potential for developing more specific inhibitors, targeted at 




The fact that a number of ion channel-targeting drugs inhibit cellular functions including 
proliferation, migration and invasion, and that others promote apoptosis, raises the possibility 
that such compounds may have utility in combination with standard of care therapies, e.g. 
chemotherapy. Furthermore, perturbation of the ionic balance within tumour cells may 
provide favourable conditions for the intracellular partitioning of certain cytotoxic drugs, 
enhancing their effectiveness. For example, in triple negative breast cancer cells, β-
adrenergic receptors and Nav1.5 colocalise and the β-adrenergic receptor competitive 
antagonist propranolol and the VGSC inhibitor ranolazine decrease Na+ currents, migration 
and invasion both when administered individually and in combination (Lee et al., 2019a). 
Downregulation of Kv10.1 with shRNA or application of the Kv10.1 inhibitor astemizole to 
glioblastoma cells sensitises them to treatment with the standard of care chemotherapeutic 
temozolomide (Sales et al., 2016). Combination of astemizole with gefitinib has been shown 
to synergistically increase apoptosis of lung cancer cells over treatment with either agent 
alone (Chavez-Lopez et al., 2017). Another example is the macrolide antibiotics, which have 
antileukemic activity alone and in combination with chemotherapeutic drugs, and this was 
shown to be due to Kv11.1 inhibition (Pillozzi et al., 2016). 
 
Riluzole has been shown to inhibit Kv11.1 and activate KCa3.1 in colon cancer cells, thus 
contributing to cisplatin uptake (Pillozzi et al., 2018). Combined administration of the KCa3.1 
activator SKA-31 and E4031 had a similar effect, which was reproducible in mouse models, 
suggesting a complex interplay between KCa3.1 and Kv11.1 (Pillozzi et al., 2018). Riluzole 
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has also been shown to activate the K2P channel (TREK-1), reducing neuropathic pain and 
depression-like symptoms induced by treatment with oxaliplatin in colon cancer mouse 
models (Poupon et al., 2018). Another potentially interesting combinatorial treatment is 
represented by the K2P3.1 and K2P9.1 channel inhibitors anandamide and ruthenium red, 
which have been shown to additively inhibit K+ currents in lung cancer cells, although the 
effect of these compounds on cell proliferation was not determined (Leithner et al., 2016). 
 
Inhibitors of Ca2+ channels have also been investigated for combinatorial therapies. The 
Cav3.x antagonist mibefradil has been shown to inhibit glioblastoma stem-like cell 
proliferation in vitro and tumour growth in a glioblastoma mouse model, and sensitises 
tumours to treatment with temozolomide (Zhang et al., 2017b). Pharmacological inhibition of 
Cav3.x channel activity with the antagonists mibefradil and pimozide also synergistically 
suppressed proliferation in several cancer cell lines (Bertolesi et al., 2002). Inhibition of 
active ion transport may also be beneficial in combinatorial treatments. For example, 
suppression of plasma membrane Ca2+ ATPase isoform 2 (PMCA2) expression was shown 
to inhibit proliferation of breast cancer cells on its own, as well as enhancing the cytotoxicity 
of doxorubicin (Peters et al., 2016). Store operated Ca2+ entry induces expression of the 
chemotherapy resistance marker MDR1 in breast cancer cells (Babaer et al., 2018). Knock 
down of ORAI1 or STIM1 thus significantly increases sensitivity to chemotherapeutic drugs 
including cisplatin, gentamycin and 5-fluorouracyl (Kondratska et al., 2014, Sun et al., 2017, 
Kischel et al., 2019). Similarly, inhibition of TRPC5, either by siRNA or by treatment with 
chloroquine or 3-methyladenine, increases sensitivity to doxorubicin in breast cancer cell 
lines (Zhang et al., 2017a). On the other hand, different studies suggest certain Ca2+ 
channels render cells more responsive to chemotherapy (Kischel et al., 2019). For example, 
TRPC1 expression is downregulated in drug-resistant ovarian cancer tissues compared with 
drug-responsive samples and cisplatin and carboplatin-resistant ovarian cancer cell lines 
were shown to also have lower levels of TRPC1 (Liu et al., 2016). TRPV2 activation with 
cannabidiol plays an important role in sensitising glioma cells to doxorubicin, carmustine and 
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temozolomide (Nabissi et al., 2012), Thus, combination of certain channel-modulating drugs 
and chemotherapeutic drugs may have value by reducing tumour chemotherapeutic 
resistance, but the situation is likely channel or cell-type dependent. 
 
Ion channel inhibition may also be advantageous in the context of standard of care 
radiotherapy. For example, antiepileptic drug use is associated with improved overall survival 
of breast cancer patients with brain metastasis receiving whole brain radiotherapy (Reddy et 
al., 2015), raising the possibility that VGSC inhibition may radiosensitise brain metastases. In 
addition, TRPM8 inhibition has been shown to radiosensitise glioblastoma cells and 
attenuate DNA repair (Klumpp et al., 2017) and TRPM2 inhibition enhances radiotherapy-
induced cell death in leukaemia cells (Klumpp et al., 2016). 
 
By targeting specific ion channels, certain inhibitors may enhance the capacity of the immune 
system to fight tumours. For example, non-small cell lung cancer patients with low serum salt 
levels respond poorly to immune check-point inhibitor therapy, illustrating potential 
interconnection between ionic balance and immune system-mediated tumour clearance 
(Fuca et al., 2018). Another study showed that an increase in extracellular K+ caused by 
tumour cell necrosis has an immunosuppressive impact on effector T cells by increasing 
intracellular K+. Upregulation of Kv1.3 in T cells resulted in K+ export, counteracting the 
immunosuppressive action of the tumour-derived K+ (Eil et al., 2016). Furthermore, high K+ in 
the tumour microenvironment maintained T cells in a stem-like state capable of dividing and 
enhancing tumour destruction (Vodnala et al., 2019). These data suggest manipulation of K+ 
flux may be effective in enhancing immunotherapeutic approaches. 
 
In summary, considerable research has been carried out towards combining current cancer 
therapies and ion channel inhibitors or developing new combinatorial treatments that 
integrate ionic targeting. Despite significant progress, there is yet much that needs to be 
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done to optimise and refine existing therapies, as well as to generate new and effective 
strategies for exploiting ionic disbalances in the tumour microenvironment. 
 
Conclusions and Future Perspectives 
 
The study of ion channel inhibitors in the context of oncology is gaining interest with time, 
particularly given the limitation of chemotherapy and targeted therapies, and the need for 
new perspectives on counteracting tumour progression and metastasis. Whilst individual ion 
channel targeting may be effective on its own in certain circumstances, a combinatorial 
approach of ion channel-targeting drugs and chemotherapy, radiotherapy and/or emerging 
immunotherapies may derive greater benefits. However, a key obstacle remains in terms of 
tumour specificity, given that many of these channels are also expressed in normal cells. 
Therefore, the use of ion channel blockers can often be accompanied by severe side effects 
and might even be lethal (Vandenberg et al., 2012).  
 
Engineering antibodies or small molecules that target tumour-specific isoforms/states of 
various ion channels has been a step forward towards increasing the sensitivity and 
specificity of ion channel-targeted therapies in cancer (Clare et al., 2000, Chioni et al., 2005, 
Hartung et al., 2011, Sette et al., 2013, Sun et al., 2016, Gilbert et al., 2017). Yet, the 
continuous dynamics of the tumour environment could limit the efficacy of these approaches 
through target mutations. Furthermore, antibody therapies are limited both by the size-
dependent tissue penetration and by the manufacturing procedure. Nevertheless, the idea of 
specifically targeting tumour-associated ion channels is worth investigating for the future. The 
capacity to distinguish between malignant and healthy ion channels could enable more 
complex therapeutic approaches such as combining ion channels inhibitors that could 
suppress tumour growth and ion channel enhancers that would induce activation and 
proliferation of immune cells, enabling those to clear the malignant tissue (Chiang et al., 
 24 
2017). However, before such complex strategies can be designed a more complete 
understanding of tumour-specific ion channel expression, function and pharmacology is 
required. 
 
In conclusion, given the strong links between ion channel function and regulation of tumour 
growth, metastasis and chemotherapy resistance, it is likely that further work in this area will 
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Table 1. Na+ channel/transporter inhibitors in cancer. 
Compound Cancer target Type of cancer 
Amiloride ENaC, NHE1  In vitro: multiple myeloma (Rojas et al., 2017), 
trophoblasts (Del Monaco et al., 2009). In vivo: 
hepatocellular carcinoma breast, gastric, colon, 
pancreatic (Matthews et al., 2011, Sparks et al., 
1983). 
Bupivacaine  VGSC, Kv11.1 In vitro: breast (Chang et al., 2014, Li et al., 2018), 




In vitro: prostate (Abdul and Hoosein, 2001), 
breast (Teichmann et al., 2014, Meng et al., 
2011), neuroblastoma (Lang et al., 1993). 
Casein kinase 1 
inhibitor IC261 
VGSC In vitro & in vivo: pancreatic cancer (Brockschmidt 




In vitro: hepatocellular carcinoma (Yang and Kim, 
2017), colon (Arimochi and Morita, 2008), multiple 
myeloma (Biber et al., 2018).  
Diclofenac VGSC In vitro and in vivo: colon, ovarian, neuroblastoma 
fibrosarcoma (Pantziarka et al., 2016). 
In vivo: breast, lung, connective tissue tumours, 





Na+/K+ ATPase In vitro: lung (Pongrakhananon et al., 2013, Lin et 
al., 2015), breast, colon, prostate, hepatocellular 
(Gould et al., 2018, Khajah et al., 2018, Shen et 
al., 2020, Zhang et al., 2008), osteosarcoma 
(Menger et al., 2012).  
In vivo: breast (Gould et al., 2018), lymphoma, 
leukaemia (Zhang et al., 2008, Haux et al., 2001), 
fibrosarcoma, colon, hepatocellular, head and 
neck (Menger et al., 2012).  
Disopyramide VGSC In vitro: breast (Fraser et al., 2005) 
Dronedarone 
 
VGSC In vitro: ovarian (Meléndez et al., 2020).  




VGSC, Kv10.1, Kv11.1  In vitro: acute myeloid leukaemia (Xia et al., 1999, 
Metts et al., 2017), colon (Arimochi and Morita, 
2006), melanoma (Gavrilova-Ruch et al., 2002, 
Parker et al., 2012), multiple myeloma (Biber et 
al., 2018).  





In vitro: neuroblastoma (Lang et al., 1993). 
In vivo: prostate (Stettner et al., 2012), breast 
(Pellegrino et al., 2018). 
Levobupivacaine VGSC, Kv11.1 In vitro: colon (Li et al., 2019), breast (Li et al., 
2018), prostate (Jose et al., 2018). 
Lidocaine VGSC In vitro: breast (Yoon et al., 2011, Chang et al., 
2014), colon (Siekmann et al., 2019), lung 
(Onganer and Djamgoz, 2005). 
In vivo: breast (Chang et al., 2014).  
Mexiletine/ 
RS100642 
VGSC, Kv11.1 In vitro: breast (Fraser et al., 2005). 
Nortriptyline  VGSC, Kv11.1 In vitro: melanoma (Parker et al., 2012), multiple 
myeloma (Biber et al., 2018). 





In vitro: breast (Yang et al., 2012), prostate (Abdul 
and Hoosein, 2001, Anderson et al., 2003, Fraser 
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et al., 2003b), lung (Onganer and Djamgoz, 
2005), neuroblastoma (Lang et al., 1993). 
In vivo: breast (Nelson et al., 2015). 
NESOpAb Neonatal Nav1.5 In vitro: breast (Brackenbury et al., 2007, Chioni et 
al., 2005). 
Propranolol VGSC In vitro: breast (Lee et al., 2019a). 
Protriptyline VGSC In vitro: osteosarcoma (Su et al., 2016), prostate 
(Chang et al., 2015).  
Quinidine VGSC, VGKC, KATP In vitro: glioma (Ru et al., 2015), breast 
(Wonderlin et al., 1995). 
In vivo: breast (Raderer et al., 1993). 
Ranolazine VGSC In vitro: breast (Driffort et al., 2014, Lee et al., 
2019a), colon (Guzel et al., 2019). 
In vivo: prostate (Bugan et al., 2019), breast 
(Driffort et al., 2014). 
Riluzole VGSC, metabotropic 
glutamate receptor 1, 
Kv11.1, K2P 
In vitro: prostate (Abdul and Hoosein, 2002b, 
Akamatsu et al., 2009, Uzun et al., 2017), 
pancreatic (Sun et al., 2019), neuroblastoma, 
glioma, lung, colon, leukaemia, myeloma 
(Lemieszek et al., 2018, Benavides-Serrato et al., 
2020, Pillozzi et al., 2018, Poupon et al., 2018). 
In vivo: breast (Speyer et al., 2012), melanoma 
(Yip et al., 2009), glioma (Zhang et al., 2015), 
glioblastoma (Benavides-Serrato et al., 2020) 
hepatocellular carcinoma (Seol et al., 2016). 
Ropivacaine VGSC, Kv11.1 In vitro: colon (Baptista-Hon et al., 2014), breast 
(Li et al., 2018)  
Tarantula peptide 
toxin HNTX-III 
VGSC In vitro: prostate (Chen et al., 2019).  
Tetracaine  VGSC In vitro: breast (Yoon et al., 2011).  
Tetrodotoxin VGSC In vitro: prostate (Grimes et al., 1995, Grimes and 
Djamgoz, 1998). 
In vivo: prostate (Yildirim et al., 2012). 
Topiramate VGSC In vitro: ovarian (Xu et al., 2018). 
In vivo: lung (Ma et al., 2011). 
Valproic acid VGSC In vitro: prostate (Abdul and Hoosein, 2001, 
Angelucci et al., 2006) breast (Olsen et al., 2004). 
In vivo: colon, prostate, gastro-oesophageal 




VGSC, NHE1 In vitro: breast (Isbilen et al., 2006, Gillet et al., 
2011, Wannous et al., 2015).  
Abbreviations: ENaC, epithelial Na+ channel; NHE1, Na+/H+ exchanger-1; VGKC, voltage-
gated K+ channel; VGSC, voltage-gated Na+ channel. 
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Table 2. K+ channel inhibitors in cancer. 
Compound Cancer target Type of cancer 
4-aminopyrimidine VGKC, KCa2.3 In vitro: breast (Potier et al., 2006), prostate 
(Fraser et al., 2003a), melanoma (Artym and 
Petty, 2002), cervical, ovarian (Han et al., 2007).  
Amiodarone Kv1.3, Kv10.1, VGSCs In vitro: prostate (Abdul and Hoosein, 2002a), 
breast (Abdul et al., 2003), glioma (Kim et al., 
2011, Chang et al., 2018). 
In vivo: breast (Lee et al., 2015). 
Anandamide K2P3.1, Kv1.2 In vitro: lung (Leithner et al., 2016), breast (De 
Petrocellis et al., 1998, Laezza et al., 2012), 
hepatocellular (Xie et al., 2012). 
In vivo: breast (Grimaldi et al., 2006). 
Antibodies Kv10.1, Kv11.1, K2P9.1 In vitro: ovarian, neuroblastoma (Gómez-Varela et 
al., 2007), prostate (Hartung et al., 2011), 
pancreatic (Sette et al., 2013, Duranti et al., 
2018), breast, colon (Duranti et al., 2018), B cell 
lymphoma (Wang et al., 2007), lung (Sun et al., 
2016). 
In vivo: breast and pancreatic (Gómez-Varela et 
al., 2007), pancreatic (Duranti et al., 2018), lung 
(Sun et al., 2016). 
Apamine KCa2.3 In vitro: breast (Potier et al., 2006).  
APETx4 Kv10.1 In vitro: neuroblastoma, melanoma, prostate 
(Moreels et al., 2017b). 
Astemizole Kv10.1, Kv11.1 In vitro: lung (Chavez-Lopez et al., 2017), prostate 
(Bernal-Ramos et al., 2017), breast, 
hepatocellular (García-Quiroz et al., 2012, de 
Guadalupe Chavez-Lopez et al., 2015). 
In vivo: breast (García-Quiroz et al., 2014), 
hepatocellular (de Guadalupe Chavez-Lopez et 
al., 2015). 
Bicalutamide KCa1.1 In vitro: breast (Khatun et al., 2018).  
Calcitriol/Calcipotriol KCa1.1, Kv10.1 In vitro: breast (García-Quiroz et al., 2012, Khatun 
et al., 2016, Khatun et al., 2018) hepatocellular 
(García-Quiroz et al., 2012).  
In vivo: breast (García-Quiroz et al., 2014). 
Charybdotoxin Kv1.3 In vitro: prostate (Fraser et al., 2003a). 
Cisapride Kv11.1 In vitro: gastric (Shao et al., 2005). 
Clofazimine  Kv1.3 In vitro: melanoma, lymphocytes, (Leanza et al., 
2012, Leanza et al., 2013b). 
In vivo: melanoma (Leanza et al., 2012). 
Clotrimazole KCa3.1 In vitro: colon (De Marchi et al., 2009), breast 
(Zhang et al., 2016), pancreatic (Bonito et al., 
2016). 
Dequalinium Kv1.3 In vitro: prostate (Abdul and Hoosein, 2002a).  
Ergtoxin Kv11.1 In vitro: ovarian (Asher et al., 2011). 
E4031 and 
Way123,398 
Kv11.1 In vitro: breast (Lansu and Gentile, 2013), ovarian 
(Asher et al., 2011), acute lymphoblastic 
leukaemia (Pillozzi et al., 2011), gastric (Crociani 
et al., 2014), colon (Crociani et al., 2013).  
In vivo: acute lymphoblastic leukaemia (Pillozzi et 
al., 2011) gastric (Crociani et al., 2014), colon 
(Crociani et al., 2013).  
Enzalutamide KCa1.1 In vitro: breast (Khatun et al., 2018)  
Glyburide KATP, Kv1.3 In vitro: prostate (Abdul and Hoosein, 2002a).  
Iberiotoxin KCa1.1 In vitro: cervical, ovarian (Han et al., 2007), glioma 
(Weaver et al., 2004).  
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Abbreviation: VGKC, voltage-gated K+ channel.  
  
Imipramine  Kv10.1 In vitro: ovarian (Asher et al., 2011). 
Macrolide antibiotics Kv11.1 In vitro and in vivo: leukaemia (Pillozzi et al., 
2016). 
Margatoxin  Kv1.3 In vitro: prostate (Fraser et al., 2003a).  
Methanandamide K2P9.1 In vitro: ovarian (Innamaa et al., 2013). 
Psora-4 Kv1.3 In vitro: melanoma, lymphocytes (Leanza et al., 
2012, Leanza et al., 2013b). 
5-(4-phenoxybutoxy) 
psoralen 
Kv1.3 In vitro: melanoma, lymphocytes (Leanza et al., 
2012, Leanza et al., 2013b). 
Purpurealidin 
analogues 
Kv10.1 In vitro: neuroblastoma, prostate, melanoma 
(Moreels et al., 2017a). 
Ruthenium red  K2P9.1 In vitro: lung (Leithner et al., 2016). 
Tamoxifen Kv11.1 In vitro and in vivo: breast (Luveta et al., 2020). 
Tetraethylammonium KCa2.3, Kv1.3 In vitro: breast (Potier et al., 2006), prostate 
(Fraser et al., 2003a), melanoma (Artym and 
Petty, 2002), cervical, ovarian (Han et al., 2007). 
TRAM-34 KCa3.1 In vitro: lymphoma (Wang et al., 2007), breast 
(Zhang et al., 2016), pancreatic (Zhang et al., 
2016), glioma (Turner et al., 2014), colon (De 
Marchi et al., 2009), melanoma (Quast et al., 
2012). 
Verapamil Kv1.3 In vitro: melanoma (Artym and Petty, 2002), 
prostate (Fraser et al., 2003a). 
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Table 3. Ca2+ channel inhibitors in cancer. 




TRP In vitro: breast (Hopkins et al., 2015), glioma 
(Bomben and Sontheimer, 2008, Bomben and 
Sontheimer, 2010). 
Bepridil VGCC In vitro: breast (Park et al., 2016, Nguyen et al., 
2017) glioma (Kim et al., 2011). 
In vivo: breast (Park et al., 2016) 
Cannabinoids TRPM8 (inhibited), 
TRPV1 (activated) 
In vitro: colon (Borrelli et al., 2014), cervical, 
glioma (Contassot et al., 2004a, Contassot et al., 
2004b), breast (Ligresti et al., 2006), 
neuroblastoma (Hamtiaux et al., 2011). 
In vivo: colon (Borrelli et al., 2014) 
Capsazepine TRPM8 In vitro: prostate (Zhang and Barritt, 2004) 
Diltiazem VGCC In vitro: prostate (Kaddour-Djebbar et al., 2012), 
breast (Timar et al., 1992, Roger et al., 2004), 
pancreatic (Woods et al., 2015)  
Felodipine VGCC In vitro: melanoma, breast (Honn et al., 1985) 
In vivo: melanoma (Honn et al., 1985) 
Fendiline VGCC In vitro: pancreatic (Woods et al., 2015, Alhothali 
et al., 2019), lung, endometrial, colon (van der 
Hoeven et al., 2013). 
Flunarizine VGCC In vitro: melanoma (Sezzi et al., 1985), multiple 
myeloma, lymphoma (Conrad et al., 2010, 
Schmeel et al., 2015)  
Flusprilene VGCC In vitro & in vivo: glioblastoma (Dong et al., 2017), 
hepatocellular (Shi et al., 2015). 
KYS05090 VGCC In vitro: ovarian (Jang et al., 2013). 
In vitro and in vivo: lung (Kang et al., 2012, Rim et 
al., 2014). 
Mibefradil VGCC In vitro: leukaemia (Huang et al., 2015), breast, 
retinoblastoma (Bertolesi et al., 2002), colon 
(Dziegielewska et al., 2014), glioblastoma (Valerie 
et al., 2013, Zhang et al., 2017b) 
In vivo: glioma and glioblastoma (Holdhoff et al., 
2017, Zhang et al., 2017b) 
Monoclonal antibody nfP2X7 In vivo: basal cell carcinoma (clinical trials) 
(Gilbert et al., 2017, Gilbert et al., 2019). 
Nifedipine VGCC In vitro: breast (Timar et al., 1992, Roger et al., 
2004, Squecco et al., 2015), melanoma (Honn et 
al., 1985), pancreatic (Woods et al., 2015) 
endometrial (Bao et al., 2012). 
In vivo: melanoma (Honn et al., 1985), colon 
(Yang and Friedlander, 2001). 
Nimodipine VGCC In vitro: melanoma, breast (Honn et al., 1984, 
Honn et al., 1985).  
In vivo: melanoma (Honn et al., 1984, Honn et al., 
1985). 





Ryanodine receptor In vitro: lung (Shin et al., 2018). 
In vivo: breast (Abdul et al., 2008). 




ORAI, TRPC1 In vitro: glioma (Bomben and Sontheimer, 2008, 
Bomben and Sontheimer, 2010). 
In vivo: breast (Yang et al., 2009).  
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Abbreviations: TRP, transient receptor potential, VGCC, voltage-gated Ca2+ channel.  
SOR-C13, SOR-C27 TRPV6 In vivo: solid tumours of epithelial origin (Phase I 
Clinical Trial) (Fu et al., 2017), ovarian (Xue et al., 
2018), prostate (Bowen et al., 2013). 
Verapamil VGCC In vitro: pancreatic (Sato et al., 1994, Zhao et al., 
2016), breast (Timar et al., 1992, Roger et al., 
2004, Berzingi et al., 2016). 
In vivo: pancreatic (Sato et al., 1994, Zhao et al., 
2016). 
Waixenicin A TRPM7 In vitro and in vivo: colon (Huang et al., 2017). 
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Table 4. Cl- channel inhibitors in cancer. 
Compound Cancer target Type of cancer  
Ani9 and derivatives ANO1 In vitro: prostate (Song et al., 2018), pancreatic, 
breast (Seo et al., 2018). 
Bumetanide NKCC1 In vitro & in vivo: glioma (Haas and Sontheimer, 
2010), colon (Malamas et al., 2015). 
CaCCinh-A01 ANO1 In vitro: prostate (Song et al., 2018), colon, lung 
(Guan et al., 2016), breast (Britschgi et al., 2013), 
oesophageal and pharyngeal squamous 
carcinoma (Bill et al., 2014), pancreatic (Sauter et 
al., 2015). 
Chlorotoxin CLC-3 In vitro and in vivo (clinical trials): 
glioma (Deshane et al., 2003, Mamelak et al., 
2006) 
DIDS Acid-induced Cl- 
channels 
Nasopharyngeal (Wang et al., 2012) 
Digallic Acid and Tannic 
Acid 
ANO1 In vitro: lymphoblastoma (Bhouri et al., 2012), 
oesophageal and pharyngeal squamous 
carcinoma (Bill et al., 2014), gingival (Darvin et al., 
2015), breast (Nie et al., 2016), prostate (Karakurt 
and Adali, 2016) 
Idebenone ANO1 In vitro: pancreatic, prostate (Seo et al., 2015) 
Luteolin ANO1 prostate (Seo et al., 2017) 
NPPBs Acid-induced Cl- 
channels 
In vitro: cervical (Shen et al., 2000), 
nasopharyngeal (Wang et al., 2012) 
Tamoxifen  Acid-induced Cl- 
channels (CLC-3) 
In vitro: hepatocellular (Mao et al., 2013), cervical 
(Shen et al., 2000), nasopharyngeal (Wang et al., 
2012).   
In vivo: breast (Luveta et al., 2020) 
T16Ainh-A01 ANO1 In vitro: pancreatic (Mazzone et al., 2012), 
prostate (Song et al., 2018), colon, lung (Guan et 
al., 2016), oesophageal and pharyngeal 





Figure 1. Potential anticancer utility of Na+, K+, Ca2+ and Cl- channel blockers. Principal 
consequences of ion channel function in cancer cells: (1) Membrane potential depolarisation 
(Yang and Brackenbury, 2013); (2) invasion and metastasis (Besson et al., 2015); (3) cell 
cycle progression and proliferation (Becchetti, 2011); (4) angiogenesis (Fiorio Pla et al., 
2012); (5) Ca2+ signalling in response to altered K+ channel activity (Illek et al., 1992). Na+, 
Ca2+, K+ and Cl- channels are represented on the plasma membrane for clarity, but some 
functions are performed by intracellularly located channels (details in main text). Key inhibitor 
classes and examples of widely studied compounds are included (see Tables for a complete 
list). Abbreviations: ENaC – epithelial Na+ channel, KCa – Ca2+ dependent K+ channels, K-
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RAS - Kirsten rat sarcoma, NKA - Na+/K+ ATPase, NKCC – Na+/ K+/Cl- co-transporter, TF – 
transcription factors, VGCC – voltage-gated Ca2+ channel, VGKC – voltage-gated K+ 
channel, VGSC – voltage gated Na+ channel.  
